Casodex (bicalutamide)

Offer Combined Androgen Blockade (CAB) to Patients with Advanced Prostate Cancer

Prostate cancer is a hormone-dependent disease that relies on androgens to advance and proliferate.1 Approximately 95% of circulating androgens come from testicular production.2

However, androgens are also produced by the adrenal glands (approximately 5%).2

  • Luteinizing hormone-releasing hormone analogs (LHRH-As) suppress testicular production of androgens to castrate levels1, 2
  • Nonsteroidal antiandrogens (NSAAs) block the binding of androgens at the receptor site1, 2
  • NSAAs, such as CASODEX 50 mg Tablets, when used with an LHRH-A as part of CAB therapy, help inhibit the growth of prostate cancer cells2, 3

CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone analog (LHRH-A) for the treatment of Stage D2 metastatic carcinoma of the prostate.

CASODEX 150 mg daily is not approved for use alone or with other treatments (see Clinical Studies section 14.2 in the full Prescribing Information).

Offer your patients proven survival

In a randomized, double-blind (for antiandrogen therapy only) study in 813 patients with untreated metastatic prostate cancer, the results for time to progression and survival were3,4:

Casodex Median

Adapted from Schellhammer PF, Sharifi R, Block NL, et al4

For time to progression and survival, CASODEX 50 mg qd plus an LHRH-A was not significantly different from Flutamide 250 tid plus an LHRH-A.3,4

Kaplan-Meier Survival Curve

Kaplan-Meier Survival Curve-adapted from Schellhammer PF, Sharifi R, Block NL, et al4

Kaplan-Meier Time to Progression

Kaplan-Meier Time to Progression-adapted from Schellhammer PF, Sharifi R, Block NL, et al4

Important Safety Information About CASODEX

References:

  1. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804-818.
  2. Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
  3. CASODEX® (bicalutamide) 50 mg Tablets full Prescribing Information, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.
  4. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997;50:330-336.

Casodex